CS
BTAI icon

Credit Suisse’s BioXcel Therapeutics BTAI Stock Holding History

Credit Suisse’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,347
Closed -$54.5K – 3069
2023
Q3 		$54.5K Sell
1,347
-619
-31% -$62.6K ﹤0.01% 3114
2023
Q2 		$209K Buy
1,966
+843
+75% +$281K ﹤0.01% 3087
2023
Q1 		$335K Buy
1,123
+249
+28% +$106K ﹤0.01% 2949
2022
Q4 		$300K Sell
874
-9
-1% -$2.18K ﹤0.01% 3043
2022
Q3 		$167K Buy
883
+5
+0.6% +$1.16K ﹤0.01% 3307
2022
Q2 		$185K Sell
878
-28
-3% -$5.89K ﹤0.01% 3358
2022
Q1 		$303K Buy
906
+58
+7% +$16.8K ﹤0.01% 3218
2021
Q4 		$276K Buy
848
+4
+0.5% +$1.72K ﹤0.01% 4150
2021
Q3 		$410K Buy
844
+66
+8% +$29K ﹤0.01% 3934
2021
Q2 		$361K Hold
778
– – ﹤0.01% 4018
2021
Q1 		$537K Sell
778
-2,269
-74% -$1.83M ﹤0.01% 3723
2020
Q4 		$2.25M Sell
3,047
-664
-18% -$517K ﹤0.01% 2731
2020
Q3 		$2.57M Buy
3,711
+712
+24% +$535K ﹤0.01% 2239
2020
Q2 		$2.54M Buy
+2,999
New +$1.96M ﹤0.01% 2192

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse's BTAI Position: Q4 2023 in Review

Credit Suisse sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 1,347 shares — an estimated $54.5K sold.

Credit Suisse first reported a position in BTAI in Q2 2020 and held it in 14 quarters. The position peaked at $2.57M in Q3 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Credit Suisse reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 1,347 BioXcel Therapeutics shares in Q4 2023, an estimated $54.5K.
  • Credit Suisse first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 14 quarters.
  • Credit Suisse's BioXcel Therapeutics position peaked at $2.57M in Q3 2020.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.